Tech

The FDA wants to pull its approval of a drug. It’s not so easy.

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 31/10/2026, 11:58:24 UTC.

Briefings

In May 2021, the FDA released a briefing on an experimental drug for rare autoimmune vasculitis, noting the drug showed slightly higher symptom remission in a study by ChemoCentryx but deemed the design suboptimal. Advisory committee members questioned whether the results were well-verified, while some patients and physicians viewed the data as potentially helpful for reducing reliance on steroids. The FDA ultimately withheld approval, citing insufficient verification of the drug's efficacy.

Key points

• The FDA released a briefing in May 2021 regarding an experimental drug for rare autoimmune vasculitis, noting the drug showed slightly higher symptom remission in a study by ChemoCentryx but deemed the design suboptimal.
• Advisory committee members questioned whether the results were well-verified, while some patients and physicians viewed the data as potentially helpful for reducing reliance on steroids.

Context

The FDA withheld approval of an experimental drug for rare autoimmune vasculitis after a study by ChemoCentryx showed slightly higher symptom remission in a May 2021 study, though the design was deemed suboptimal by the agency and some committee members.

Limitations

Evidence is limited to a single May 2021 FDA briefing document; specific committee member names are not identified, and the study's limitations are described generally without detailed statistical analysis.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 31/10/2026, 13:07:16 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihva75uwcdo4aoj4qufw5fhxtt5mjvukttcbtzj3a2y7txtzfkvby